Skip to main content
SpringerLink
Log in

Antineoplastic Agents

  • Chapter
  • First Online:
Antiepileptic Drug Interactions

  • 1440 Accesses

Abstract

Carbamazepine Carbamazepine enhances the mean plasma clearance of 9-aminocamptothecin by 68 % and can decrease median plasma 9-aminocamptothecin levels by 67 % 1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Grossman SA, Hochberg F, Fisher J, Chen TL, Kim L, Gregory R, Grochow LB, Piantadosi S. Increased 9-aminocamptothecin dose requirements in patients with anticonvulsants. Cancer Chemother Pharmacol. 1998;42:118–26.

    Article  PubMed  CAS  Google Scholar 

  2. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993;33:181–6.

    Article  PubMed  CAS  Google Scholar 

  3. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 Enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol. 2005;72:255–60.

    Article  PubMed  CAS  Google Scholar 

  4. Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol. 2008;10:190–8.

    Article  PubMed  CAS  Google Scholar 

  5. Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitroso-urea-cisplatine-based chemotherapy associated with valproate: increase of haematologic activity. Ann Oncol. 2001;12:217–9.

    Article  PubMed  CAS  Google Scholar 

  6. Ekhart C, Rodenhuis S, Beijnen JH, Huitema ADR. Carbamazepine induces bioactivation of cyclophosphamide and thiotepa. Cancer Chemother Pharmacol. 2009;63:543–7.

    Article  PubMed  Google Scholar 

  7. de Jong ME, Huitema ADR, van Dam AM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol. 2005;55:507–10.

    Article  Google Scholar 

  8. Relling MV, Pui CH, Sandlund JT, Rivera GK, Hancock ML, Boyett JM, Schuetz EG. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukemia. Lancet. 2000;356:285–90.

    Article  PubMed  CAS  Google Scholar 

  9. Rodman JH, Murry DJ, Madden T, Santana VM. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. J Clin Oncol. 1994;12:2390–7.

    PubMed  CAS  Google Scholar 

  10. Chhun S, Verstuyft C, Rizzo-Padoin N, Simoneau G, Becquemont L, Peretti I, Swaisland A, Wortelboer R, Bergmann JF, Mouly S. Gefitinib-phenytoin interaction is not correlated with the 14C-erythromycin breath test in healthy male volunteers. Br J Clin Pharmacol. 2009;68:226–37.

    Article  PubMed  CAS  Google Scholar 

  11. van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, Dittrich CV, de Jong MJA, Brandes A, Frenay M, Carpentier AF, Cholllet P, Oliveira J, Baron B, Lacombe D, Schuessler M, Fumoleau P. European Organisation for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol.2003;14(12):1732–4.

    Article  PubMed  Google Scholar 

  12. Lokiec F, Santoni J, Weill S, Tubiana-Hulin M. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. Anticancer Drugs. 1996;7:893–6.

    Article  PubMed  CAS  Google Scholar 

  13. Ghosn M, Carde P, Leclerq B, Flamant F, Friedman S, Droz JP, Hayat M. Ifosfamide/mesa related encephalopathy: a case report with possible role of phenobarbital in enhancing neurotoxicity. Bull Cancer. 1988;74:391–2.

    Google Scholar 

  14. Ducharme MP, Bernstein ML, Granvil CP, Gehrcke B, Wainer IW. Phenytoin-induced alteration in the N-dechloroethylation of ­ifosfamide stereoisomers. Cancer Chemother Pharmacol. 1997;40:531–2.

    Article  PubMed  CAS  Google Scholar 

  15. Pursche S, Schleyer E, von Bonin M, Ehningger G, Said SM, Prondzinsky R, Illmer T, Wang Y, Hosius C, Nikolova Z, Bornhauser M, Dresemann G. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol. 2008;3:198–203.

    Article  PubMed  CAS  Google Scholar 

  16. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23:9359–68.

    Article  PubMed  CAS  Google Scholar 

  17. Gajjar A, Chintagumpala MM, Bowers DC, Jones-Wallace D, Stewart CF, Crews KR. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in patients who have high-grade gliomas receiving enzyme-inducing anticonvulsant therapy. Cancer. 2003;95 (Suppl):2374–80.

    Article  Google Scholar 

  18. Innocenti F, Undevia SD, Ramirez J, Mani S, Schilsky RL, Vogelzang NJ, Prado M, Ratain MJ. A phase I trial of pharmacological modulation or irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004;76:490–502.

    Article  PubMed  CAS  Google Scholar 

  19. Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003;9:2940–9.

    PubMed  CAS  Google Scholar 

  20. de Jong FA, van der Bol JM, Mathijssen RHJ, Loos WJ, Mathot RAA, Kitzen JJEM, van den Bent MJ, Verweij J. Irinotecan chemotherapy during valproic acid treatment. Pharmacokinetic interaction and hepatotoxicity. Cancer Biol Ther. 2007;6:1368–74.

    PubMed  Google Scholar 

  21. Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelen A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2009;67:421–6.

    Article  PubMed  CAS  Google Scholar 

  22. Riva M, Landonio G, Defanti CA, Siena S. The effect of anticonvulsant drugs on blood levels of methotrexate. J Neurooncol. 2000;48:249–50.

    Article  PubMed  CAS  Google Scholar 

  23. Chang SM, Kuhn JG, Rizzo J, Robins HA, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Prados MD. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American brain tumor consortium report. J Clin Oncol. 1998;16:2188–94.

    PubMed  CAS  Google Scholar 

  24. Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther. 1997;62:225–9.

    Article  PubMed  CAS  Google Scholar 

  25. Grossman SA, Carson KA, Batchelo TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006;12:5174–81.

    Article  PubMed  CAS  Google Scholar 

  26. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medication. J Clin Pharmacol. 2007;47:1430–9.

    Article  PubMed  CAS  Google Scholar 

  27. Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol. 1992;10:311–5.

    PubMed  CAS  Google Scholar 

  28. de Jong ME, Huitema ADR, van Dam SM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol. 2005;55:507–10.

    Article  Google Scholar 

  29. Zamboni WC, Gajja AJ, Heideman RL, Beijnen JH, Rosing H, Houghton PJ, Stewart CF. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin Cancer Res. 1998;4:783–9.

    PubMed  CAS  Google Scholar 

  30. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther. 1999;66:589–93.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCL-Institute of Neurology Department of Clinical and Experimental Epilepsy, Queen Square, London, London

    P. N. Patsalos

  2. Epilepsy Society Chalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire, UK

    P. N. Patsalos

Authors
  1. P. N. Patsalos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Patsalos, P.N. (2013). Antineoplastic Agents. In: Antiepileptic Drug Interactions. Springer, London. https://doi.org/10.1007/978-1-4471-2434-4_57

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2434-4_57

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2433-7

  • Online ISBN: 978-1-4471-2434-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation